Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2019-11-20 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
独立董事关于昆药集团九届十六次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding several company matters: the use of idle funds for investment, the use of idle raised funds for cash management, and the unlocking of restricted stock incentive plans. It references compliance with stock exchange rules and company articles but does not contain financial statements or detailed financial results. The document is a formal opinion on governance and compliance matters related to board decisions and shareholder interests, typical of board or management information disclosures. It is not an annual report, audit report, earnings release, or any other financial report. Therefore, the best fitting category is Board/Management Information (MANG). The document length is short (1591 characters), and it is not merely an announcement of a report but an opinion document itself.
2019-11-20 Chinese
关于子公司昆明中药厂有限公司在云南滇中新区设立全资医药流通子公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group regarding the establishment of a wholly-owned pharmaceutical distribution subsidiary by its subsidiary Kunming Chinese Medicine Factory Co., Ltd. It details the investment amount, purpose, and risk analysis. The document is short (1162 characters) and focuses on a corporate action related to investment and subsidiary establishment, not a financial report or detailed management discussion. It is not an annual or interim report, earnings release, or audit report. It is also not a regulatory certification or voting result. The content fits best with a Capital/Financing Update (CAP) as it announces a new investment and capital allocation for a subsidiary. Therefore, the classification is CAP with high confidence.
2019-11-20 Chinese
昆药商业怒江医药有限公司清产核资专项审计报告
Regulatory Filings
2019-11-20 Chinese
关于子公司昆药集团医药商业有限公司增资控股云南昆康企业管理有限公司的公告
Capital/Financing Update Classification · 100% confidence The document is an official announcement by Kunming Pharmaceutical Group Co., Ltd. regarding a capital increase investment in a subsidiary company, Yunnan Kunkang Enterprise Management Co., Ltd. It details the investment amount, shareholding changes, audit reports, and risk analysis related to this transaction. The document is structured as a formal announcement of a financing activity involving equity investment and capital structure change. It does not contain comprehensive financial statements or periodic financial results, nor is it a report or transcript. The content fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes.
2019-11-20 Chinese
关于2017年限制性股票激励计划首次授予部分第二期解除限售条件成就的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the achievement of conditions for the second phase of lifting restrictions on restricted stock granted under the 2017 restricted stock incentive plan. It details the approval process, conditions met, number of shares and recipients involved, and includes opinions from the board, independent directors, supervisory board, legal counsel, and financial advisors. The content focuses on the lifting of restrictions on stock incentives, which is a capital change event related to share issuance and stock incentives. It is not a full financial report, earnings release, or management discussion, nor is it a regulatory filing or announcement of a report publication. The document is a formal announcement about a share capital change event (lifting of restrictions on restricted stock). Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length (7868 characters) supports it being a full announcement rather than a brief notice or a report publication announcement.
2019-11-20 Chinese
德恒昆明关于昆药集团2017年限制性股票激励计划首次授予部分第二期限售解除的法律意见
Audit Report / Information Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the second phase of lifting restrictions on shares granted under a 2017 restricted stock incentive plan of Kunming Pharmaceutical Group Co., Ltd. It details the approval, authorization, conditions met, and the number of shares eligible for lifting restrictions. The document is a standalone legal opinion related to stock incentive plans and share restrictions, not a full financial report, earnings release, or management discussion. It does not contain financial statements or earnings data but focuses on legal compliance and authorization related to share restrictions. This fits best under the category of Audit Report / Information (AR), which includes applied accounting principles and regulatory or internal compliance reports, excluding full annual or interim reports. It is not a report publication announcement or regulatory filing as it contains substantive legal opinion content. Therefore, the classification is AR with high confidence. FY 2019
2019-11-20 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.